Press Room

There are 4 item(s) tagged with the keyword "ViaCyte".

1. Stem cells show promise for reversing Type 2 diabetes

Scientists at the University of British Columbia and BetaLogics, part of Janssen Research & Development, LLC have shown for the first time that Type 2 diabetes can be effectively treated with a combination of specially-cultured stem cells and conventional diabetes drugs.


2. ViaCyte Receives Clearance from Health Canada for Diabetes Clinical Trial

ViaCyte, Inc., a privately-held regenerative medicine company with the first stem cell-derived islet replacement therapy for the treatment of diabetes in clinical trials, has received a No Objection Letter from Health Canada providing clearance to proceed with sites in Canada for the Company's ...


3. JDRF Partner ViaCyte to Immediately Initiate Type 1 Diabetes Clinical Trial

JDRF’s partner ViaCyte recently announced the U.S. Food and Drug Administration (FDA) is allowing them to move forward with a clinical trial of its innovative type 1 diabetes (T1D) encapsulated cell replacement therapy called VC-01™ product candidate.


4. JDRF to Provide Additional Support for Upcoming Clinical Trial of ViaCyte's Encapsulated Cell Therapy for Type 1 Diabetes

JDRF, the world’s largest non-profit supporter of type 1 diabetes (T1D) research, and ViaCyte, Inc., a leading regenerative medicine company, jointly announced that JDRF is providing additional milestone-based funding for the continued development of ViaCyte’s VC-01™ ...


Lets turn type one into type none